CLEAR
CLEAR Registry Study: An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-UM Multigene Assay Results and Associated Patient Outcomes.
Sponsor study identifier
observational
93
0 countries
N/A
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2022
Actual (reported)Study Completion
April 2022
Actual (reported)Uveal Melanoma is a rare cancer with approximately 3,000 cases diagnosed in the US every year. Nearly half of these experience spread of their cancer outside the eye. The DecisionDx-UM gene expression test classifies an individual's tumor as low risk (class 1) or high risk (class 2) of spreading. This study is being done to collect information about how physicians are using the DecisionDx-UM results to design individual treatment plans. It will also track outcomes or the uveal melanoma population that received DecisionDx-UM testing.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2022
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
February 13, 2015
Actual (reported)March 3, 2015
Actual (reported)April 2022
Actual (reported)April 2022
Actual (reported)documentation of clinical application of results obtained from DecisionDx-UM multi-gene assay
Physician treatment plan with regards to surveillance regimen as well as treatment referral pattern
Approximately 3-6 weeks after biopsy of uveal tumor
Time to metastasis
Patients followed for up to 10 years, measurement for metastatic event performed at 6 month intervals
changes in health care costs
Patients followed for up to 10 years at 6 month intervals
Patients diagnosed with uveal melanoma and determined by their treating physician to be appropriate for DecisionDx-UM testing.
Plasseraud KM, Cook RW, Tsai T, Shildkrot Y, Middlebrook B, Maetzold D, Wilkinson J, Stone J, Johnson C, Oelschlager K, Aaberg TM. Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. J Oncol. 2016;2016:5325762. doi: 10.1155/2016/5325762. Epub 2016 Jun 30.
Robert Cook, PhD
Castle Biosciences Inc.
93 participants (actual enrollment reported by the registry).
First Submitted
February 13, 2015
First Posted
March 3, 2015
Study Start
March 2010
Date type not reportedThis date has not been verified as actual or estimated.
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Contact the study team to confirm eligibility.
Primary Completion
April 2022
Actual (reported)Study Completion
April 2022
Actual (reported)Last Updated
May 16, 2022
Record last verified: 2022-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: